Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

[1]  A. Cerulli,et al.  Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. , 2005, Clinical therapeutics.

[2]  K. Meyer,et al.  Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis , 2009, Current medical research and opinion.

[3]  Anthony J. Culyer,et al.  Costs of fall injuries in the STRIDE study: an economic evaluation of healthcare system heterogeneity and heterogeneity of treatment effect , 2014, Cost Effectiveness and Resource Allocation.

[4]  M. Brosa,et al.  Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  A David Paltiel,et al.  Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  P. Auvinen,et al.  Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective , 2010, International Journal of Technology Assessment in Health Care.

[7]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[8]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  J. Mar,et al.  Calculation of Prevalence with Markov Models: Budget Impact Analysis of Thrombolysis for Stroke , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  G. Colombo,et al.  Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. , 2004, Clinical therapeutics.

[11]  J. Mauskopf.  Meeting the NICE requirements: a Markov model approach. , 2000, Value in Health.

[12]  Javier Mar,et al.  Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  M. Drummond,et al.  Developing Guidance for Budget Impact Analysis , 2012, PharmacoEconomics.

[14]  William Hollingworth,et al.  Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  J. Sung,et al.  Health Plan Budget Impact Analysis for Pimecrolimus , 2005, Journal of Managed Care Pharmacy.

[16]  J. Caro,et al.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  L. Garattini,et al.  Budget impact analysis in economic evaluation: a proposal for a clearer definition , 2011, The European Journal of Health Economics.

[18]  J. Mauskopf,et al.  Prevalence-based economic evaluation. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  D. Costagliola,et al.  Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France , 2012, PharmacoEconomics.

[20]  T. Mittendorf,et al.  Practical issues in handling data input and uncertainty in a budget impact analysis , 2010, The European Journal of Health Economics.

[21]  M. Hutchinson,et al.  A budget impact analysis of natalizumab use in Ireland , 2012, Irish Journal of Medical Science.

[22]  James G. Xenakis,et al.  Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials* , 2006, Current medical research and opinion.

[23]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  K. Srivathsan,et al.  Newer Oral Anticoagulant Agents: A New Era in Medicine , 2012, Current cardiology reviews.

[25]  D. Lubeck,et al.  Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. , 2008, Clinical therapeutics.

[26]  E. Orlewska,et al.  Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  S. G. Martí,et al.  [Budgetary impact analysis in health: update with a model using a generic approach]. , 2011, Revista peruana de medicina experimental y salud publica.

[29]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[30]  R. Walensky,et al.  Expanded HIV Screening in the U.S.: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis , 2010 .

[31]  M. Brosa,et al.  Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario , 2005 .